Publications by Professor Alan Calvert - ePrints

Browsing publications by Professor Alan Calvert.

Newcastle Authors	Title	Year
Professor Alan Calvert Professor Ruth Plummer	Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer	2014
Professor Ruth Plummer Dr Evan Mulligan Professor Nicola Curtin Professor Alan Calvert	A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation	2013
Dr Jane Margetts Dr Yvette Drew Dr Peter Stephens Professor Alan Calvert Professor Ruth Plummer et al.	Erratum to: Phase I study of PM00104 (Zalypsis (R)) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors (vol 31, pg 623, 2013 Doi: 10.1007/s10637-012-9843-5)	2013
Professor Ruth Plummer Professor Alan Calvert	Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma	2013
Professor Ruth Plummer Professor Alan Calvert	Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas	2011
Dr Joyce Nutt Kieran O'Toole Dr Fiona Black Mike Cole Professor Ruth Plummer et al.	Expression of methylthioadenosine phosphorylase (MTAP) in malignant pleural mesothelioma (MPM) and its implication for pemetrexed-based chemotherapy	2010
Dr Peter Stephens Professor Alan Calvert Professor Ruth Plummer	Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors	2010
Professor Alan Calvert Professor Ruth Plummer	Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours	2010
Dr Joyce Nutt Kieran O'Toole Dr Fiona Black Amy Quinn Professor Alan Calvert et al.	The role of folate receptor alpha (FR alpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy	2010
Amy Quinn Professor Alan Calvert Professor John Lunec	A Monoclonal Antibody for Detection of Folylpolyglutamate Synthetase in Paraffin Embedded Tissues	2009
Professor Alan Calvert	A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer	2009
Dr Joyce Nutt Kieran O'Toole Dr Fiona Black Professor Ruth Plummer Professor Alan Calvert et al.	Expression of folate receptor alpha (FRa) in malignant pleural mesothelioma patients by immunohistochemistry: a clinico-pathological analysis	2009
Professor Alan Calvert	Phase 0 clinical trials: Recommendations from the task force on methodology for the development of innovative cancer therapies	2009
Professor Ruth Plummer Melanie Griffin Dr Sally Coulthard Julieann Sludden Professor Alan Calvert et al.	Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors	2009
Professor Alan Calvert	Design and conduct of phase II studies of targeted anticancer therapy: Recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT)	2008
Professor Alan Calvert	Endpoints and other considerations in phase I studies of targeted anticancer therapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT)	2008
Sarah Wilkinson Dr Ali Kucukmetin Dr Steven Darby Vincent Gnanapragasam Professor Alan Calvert et al.	Expression of gonadotrophin releasing hormone receptor I is a favorable prognostic factor in epithelial ovarian cancer	2008
Professor Ruth Plummer Professor Alan Calvert	Mechanisms of chemoresistance to alkylating agents in malignant glioma.	2008
Professor Ruth Plummer Professor Alan Calvert	Open-label, non-randomised, inter-individual dose escalation of ZK 304709 with the evaluation of safety, tolerability, pharmacokinetics, oral bioavailability and orientating efficacy after daily administration in patients with advanced cancer (7 d treatment and 14 d recovery)	2008
Professor Alan Calvert Professor Ruth Plummer Professor Nicola Curtin Professor Richard Edmondson Dr Yvette Drew et al.	PARP inhibitors in cancer treatment	2008
Professor Alan Calvert Professor Nicola Curtin Professor Ruth Plummer	PARP inhibitors in ovarian cancer	2008
Professor Ruth Plummer Professor Alan Calvert	Phase I study of the novel anti-cancer drug PM00104 as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors or lymphoma	2008
Professor Ruth Plummer Dr Christopher Jones Professor Nicola Curtin Professor Alan Boddy Professor Herbie Newell et al.	Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors	2008
Professor Alan Calvert Professor Ruth Plummer	The Development of Phase I Cancer Trial Methodologies: the Use of Pharmacokinetic and Pharmacodynamic End Points Sets the Scene for Phase 0 Cancer Clinical Trials	2008
Dr Yvette Drew Professor Alan Calvert	The Potential of PARP Inhibitors in Genetic Breast and Ovarian Cancers	2008
Dr Yvette Drew Professor Alan Calvert	The potential of PARP inhibitors in genetic breast and ovarian cancers	2008
Professor Ruth Plummer Professor Alan Calvert	[Meeting Abstract] A phase 1b study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI	2007
Professor Alan Calvert Professor John Lunec	A novel monoclonal antibody for detection of folate receptor alpha in paraffin-embedded tissues	2007
Professor Ruth Plummer Rebecca Perrett Professor Alan Calvert	A phase I and pharmacokinetic (PK) study of BIBW 2992, an oral irreversible dual EGFR/HER2 inhibitor	2007
Professor Alan Calvert Dr Fathi Azribi Rebecca Perrett Professor Ruth Plummer	Activity of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, in non-small cell lung cancer (NSCLC) with mutated EGFR	2007
Dr Michael Cullen Professor Alan Calvert	Correlation of pemetrexed (PEM) NSCLC exposure-response relationships (ERRS) to clinical study results from western and Japanese patient populations	2007
Dr Jo Lee Dr Mark Verrill Julieann Sludden Melanie Griffin Sharon Erb et al.	Pharmacogenetic influences on outcome from AC chemotherapy in the treatment of breast cancer	2007
Professor Ruth Plummer Dr Louise Li Rebecca Perrett Professor Alan Calvert	Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers	2007
Professor Alan Calvert Professor Alan Boddy	Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: A study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group	2007
Professor Ruth Plummer Professor Alan Calvert	Targeting poly(ADP-ribose) polymerase: A two-armed strategy for cancer therapy	2007
Professor Ruth Plummer Rebecca Perrett Professor Alan Calvert	A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumours	2006
Professor Ruth Plummer Professor Alan Calvert	First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AGO14699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM)	2006
Professor Ruth Plummer Dr Louise Li Rebecca Perrett Professor Alan Calvert	Phase I study of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, showing activity in tumours with mutated EGFR	2006
Professor Ruth Plummer Professor Alan Calvert	Phase I study of ispinesib in combination with carboplatin in patients with advanced solid tumors	2006
Dr Yan Zhao Huw Thomas Michael Batey Dr Ian Cowell Professor Roger Griffin et al.	Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441	2006
Professor Ruth Plummer Rebecca Perrett Professor Alan Calvert	A phase 1 dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumors	2005
Mark Leslie Julieann Sludden Professor Ruth Plummer Professor Alastair Greystoke Professor Alan Calvert et al.	A phase I and pharmacodynamic study of a 7 day infusion schedule of the DNMT1 antisense compound MG98.	2005
Professor Alan Boddy Professor Ruth Plummer Julieann Sludden Melanie Griffin Dr Mark Verrill et al.	A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules	2005
Professor Ruth Plummer Professor Alan Boddy Professor Nicola Curtin Professor Herbie Newell Lynsey Robson et al.	Final clinical, pharmacokinetic and pharmacodynamic results of the phase I study of the novel poly(ADP-ribose)polymerase (PARP) inhibitor, AG014699, in combination with temozolomide	2005
Professor Ruth Plummer Dr Christopher Jones Lynsey Robson Professor Alan Calvert	First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors	2005
Professor Alan Calvert	Fishing for new drugs	2005
Dr Ian Hardcastle Dr Shafiq Ahmed Professor Alan Calvert Professor Nicola Curtin Gillian Farnie et al.	Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction	2005
Professor Ruth Plummer Professor Alan Calvert	Phase I and pharmacokinetic study of HGS-ETR2, a fully human agonistic monoclonal antibody to TRAIL-R2, in patients with advanced solid malignancies	2005
Professor Alan Calvert	Phase I and pharmacokinetic study of HGS-ETR2, a human monoclonal antibody to TRAIL R2, in patients with advanced solid malignancies.	2005
Dr Ashraf Azzabi Dr Andrew Hughes Dr Paula Calvert Professor Ruth Plummer Melanie Griffin et al.	Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations	2005
Dr Graham Dark Professor Alan Calvert	Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: A trial of the national cancer institute of Canada clinical trials group	2005
Professor Ruth Plummer Dr Christopher Jones Professor Alan Boddy Professor Alan Calvert Professor Herbie Newell et al.	Temozolomide pharmacodynamics in patients with metastatic melanoma: DNA damage and activity of repair enzymes O⁶-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1	2005
Professor Alan Calvert Professor Ruth Plummer	The effect of erlotinib on CYP3A4 activity, as quantified by the erythromycin breath test and oral midazolam kinetics in cancer patients: Preliminary results.	2005
Professor Alan Calvert	A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-895 1f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer	2004
Dr Christopher Calabrese Michael Batey Professor Alan Calvert Professor barbara Durkacz Suzanne Kyle et al.	Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361	2004
Professor Alan Calvert	Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer	2004
Dr Christopher Calabrese Professor Nicola Curtin Suzanne Kyle Huw Thomas Lan Wang et al.	Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1- hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase	2004
Professor Nicola Curtin Lan Wang Suzanne Kyle Dr Christine Arris Professor barbara Durkacz et al.	Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells	2004
Professor Alan Calvert	Phase Ib/Il dose-escalation trial evaluating the safety and tolerability of EP0906 plus capecitabine in patients with advanced cancer.	2004
Professor Alan Calvert	Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, investigational drug branch for breast cancer and the new drug development group study	2004
Professor Nicola Curtin Hannah Barlow Professor Alan Calvert Richard Davison Emeritus Professor Bernard Golding et al.	Resistance-modifying agents. 11. Pyrimido[5,4-d]pyrimidine modulators of antitumor drug activity. Synthesis and structure-activity relationships for nucleoside transport inhibition and binding to α₁-acid glycoprotein	2004
Professor Alan Boddy Gordon Taylor Dr Andrew Hughes Professor Alan Calvert Professor Herbie Newell et al.	2-[¹¹C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337	2003
Professor Ruth Plummer Dr Andrew Hughes Dr Martin Highley Dr Sathyarathna Gokul Professor Alan Calvert et al.	A phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitor	2003
Professor Alan Calvert	Cancer drug development in Europe: A selection of new agents under development at the European Drug Development Network	2003
Professor Alan Calvert	Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials	2003
Tyrone John Professor Andrew Pearson Professor Alan Calvert Dr Michael Tilby	Determination, by ICP-MS, of background and BBR 3464 induced levels of platinum bound to DNA isolated from blood cells: A comparison of the sensitivity of the Perkin Elmer Sciex Elan 6000 and the thermofinnigan Neptune instruments	2003
Professor Alan Calvert	Developing drugs for cancer: Striking balance between clinical pragmatism and scientific allure	2003
Dr Christopher Calabrese Michael Batey Huw Thomas Professor barbara Durkacz Lan Wang et al.	Identification of potent nontoxic poly(ADP-ribose) polymerase-1 inhibitors: Chemopotentiation and pharmacological studies	2003
Professor Alan Calvert	Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors	2003
Professor Alan Calvert	Pemetrexed (Alimta): A promising new agent for the treatment of breast cancer	2003
Dr Mark Verrill Professor Alan Boddy Julieann Sludden Kevin Fishwick Lynsey Robson et al.	Phase 1 pharmacokinetic (PK) study of CT-2103 given Q2 or Q3 weeks in patients with solid tumors	2003
Professor Alan Calvert	Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors	2003
Professor Alan Calvert	Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines	2003
Tyrone John Professor Alan Calvert Dr Michael Tilby	Sensitive determination of BBR 3464 and cisplatin DNA adduct levels in clinical samples using ICP-MS and PIMMS	2003
Kerry Louise Sayle Dr Johanne Bentley Professor Alan Calvert Dr YuZhu Cheng Professor Nicola Curtin et al.	Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2	2003
Professor Nicola Curtin Professor Herbie Newell Professor Alan Calvert Professor Roger Griffin Emeritus Professor Bernard Golding et al.	Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors	2003
Professor Alan Calvert	Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies	2002
Professor Alan Calvert	A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer	2002
Professor Alan Calvert	Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial	2002
Professor Alan Calvert	Effect of temozolomide on central nervous system relapse in patients with advanced melanoma	2002
Professor Alan Calvert Dr Jane Cassidy	Efficacy, safety, and cost of new anticancer drugs - Pessimistic conclusion was not justified	2002
Professor Alan Calvert	Efficacy, safety, and cost of new anticancer drugs; pessimistic conclusion was not justified.	2002
Professor Alan Calvert	Folate status and the safety profile of antifolates	2002
Professor Alan Calvert	Future directions in the development of pemetrexed	2002
Professor Alan Calvert	Homocysteine and methylmalonic acid: Markers to predict and avoid toxicity from pemetrexed therapy	2002
Professor John Lunec Professor Alan Calvert	Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism	2002
Dr Christopher Calabrese Professor Nicola Curtin Suzanne Kyle Huw Thomas Lan Wang et al.	Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis, and X-ray cocrystal structure	2002
Professor Alan Calvert	Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial	2002
Professor Alan Calvert	Patterns of elevation of plasma 2 '-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331	2002
Professor Alan Calvert	Pemetrexed safety and dosing strategy	2002
Professor Alan Boddy Dr Mark Verrill Julieann Sludden Kevin Fishwick Lynsey Robson et al.	Pharmacological study of CT-2103 (XyotaxTM), a poly(L-glutamic acid)-paclitaxel conjugate administered every 3 weeks or every 2 weeks in a phase I study	2002
Professor Ruth Plummer Dr Paula Calvert Professor Alan Calvert	Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies	2002
Dr Andrew Hughes Dr Paula Calvert Dr Ashraf Azzabi Professor Ruth Plummer Melanie Griffin et al.	Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma	2002
Professor Alan Calvert	Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types	2002
Professor Alan Calvert	Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies	2002
Michael Batey Dr Ashraf Azzabi Professor Herbie Newell Professor Alan Calvert Professor Alan Boddy et al.	Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF)	2002
Michael Batey Dr Ashraf Azzabi Professor Herbie Newell Professor Alan Calvert Professor Alan Boddy et al.	Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF)	2002
Huw Thomas Mike Cole Suzanne Elliott Professor Herbie Newell Professor Alan Calvert et al.	Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide	2002
Dr Andrew Simpson Dr Paula Calvert Julieann Sludden Professor Alan Boddy Melanie Griffin et al.	Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules	2002
Dr Andrew Hughes Dr Ashraf Azzabi Professor Ruth Plummer Dr Jane Margetts Kevin Fishwick et al.	A phase I dose escalation study of doxorubicin in combination with pemetrexed (Alimta (R), multitargeted antifolate).	2001
Professor Alan Calvert	A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer	2001
Professor Alan Calvert	Activity of the dolastatin analogue, LU103793, in malignant melanoma	2001
Professor Nicola Curtin Dr Stephen Barton Michael Batey Dr Christopher Calabrese Professor Alan Calvert et al.	Anti-cancer chemosensitization in vitro and in vivo by a novel potent poly(ADP-ribose) polymerase (PARP1) inhibitor, TBI-361.	2001
Professor Herbie Newell Professor Alan Calvert Professor Nicola Curtin	Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro	2001
Professor Alan Boddy Dr Martin Highley Dr John Fenwick Professor Alan Calvert	Estimation of glomerular filtration rate in cancer patients	2001
Peter Smith Huw Thomas Hannah Barlow Professor Roger Griffin Emeritus Professor Bernard Golding et al.	In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity	2001
Professor Alan Calvert Professor Nicola Curtin Emeritus Professor Bernard Golding Professor Roger Griffin Dr Ian Hardcastle et al.	Inhibiting the MDM2-p53 interaction using low molecular weight compounds	2001
Professor Alan Boddy Melanie Griffin Julieann Sludden Huw Thomas Kevin Fishwick et al.	Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer	2001
Professor Alan Boddy Dr Mark Verrill Julieann Sludden Melanie Griffin Kevin Fishwick et al.	Phase I and pharmacological study of CT-2103, a poly(L-glutamic acid)-paclitaxel conjugate	2001
Professor Alan Calvert	Randomized double-blind phase II survival study comparing immunization with the anti idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer	2001
Professor Martin Noble Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Dr Ashleigh Gibson et al.	Structural and thermodynamic validation of inactive cdk2 as a template for structure-based drug design	2001
Professor Martin Noble Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Emeritus Professor Bernard Golding et al.	Structure based design of a potent inhibitor of cdk2	2001
Peter Smith Huw Thomas Hannah Barlow Professor Roger Griffin Emeritus Professor Bernard Golding et al.	In vitro activity and in vivo pharmacology of two novel nucleoside transport inhibitors, NU3108 and NU3121	2000
Dr Paula Calvert Dr Ashraf Azzabi Dr Andrew Hughes Professor Ruth Plummer Angela Robinson et al.	A phase I clinical and pharmacokinetic study of EPO906 (epothilone B) in patients with advanced solid tumours.	2000
Professor Alan Calvert Dr Paula Calvert Angela Robinson	An intermittent phase I and pharmacokinetic study of BBR3464, a novel cationic triplatinum complex	2000
Professor Alan Calvert	Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG)	2000
Professor Nicola Curtin Professor Alan Calvert Professor barbara Durkacz Professor Roger Griffin Emeritus Professor Bernard Golding et al.	Chemopotentiation studies with two classes of potent (polyADP-ribose) polymerase (PARP) inhibitors in human lung and colon carcinoma cell lines.	2000
Dr Andrew Hughes Melanie Griffin Professor Herbie Newell Professor Alan Calvert Professor Alan Boddy et al.	Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq(TM)) and paclitaxel	2000
Dr Christopher Calabrese Professor Nicola Curtin Michael Batey Huw Thomas Suzanne Kyle et al.	Design and evaluation of novel potent inhibitors of poly (ADP-ribose) polymerase	2000
Professor Roger Griffin Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Dr Ashleigh Gibson et al.	Design, synthesis, and biological evaluation of O-6-alkylguanine and O-4-alkylpyrimidine cyclin-dependent kinase inhibitors	2000
Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Dr Ashleigh Gibson Emeritus Professor Bernard Golding et al.	Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles	2000
Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Professor Jane Endicott Emeritus Professor Bernard Golding et al.	Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles	2000
Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Emeritus Professor Bernard Golding Professor Roger Griffin et al.	O6-substituted guanines and 4-substituted pyrimidines: a novel class of antiproliferative cyclin dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.	2000
Professor Alan Boddy Melanie Griffin Julieann Sludden Huw Thomas Kevin Fishwick et al.	Paclitaxel and carboplatin dose-intensity and duration of infusion in the treatment of ovarian cancer	2000
Huw Thomas Professor Alan Calvert Professor Alan Boddy	Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumours	2000
Dr Paula Calvert Professor Alan Calvert	Phase II clinical and pharmacokinetic study of exatecan mesylate (DX-8951f) in patients with advanced ovarian cancer, refractory to, or relapsed after platinum and taxane.	2000
Lan Wang Suzanne Kyle Alex White Professor Alan Calvert Professor Nicola Curtin et al.	Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines	2000
Professor Roger Griffin Dr Christine Arris Dr Christine Bleasdale Professor Alan Calvert Professor Nicola Curtin et al.	Resistance-modifying agents. 8. Inhibition of O⁶-alkylguanine-DNA alkyltransferase by O⁶-alkenyl-, O⁶-cycloalkenyl-, and O⁶-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O⁶-(1-cyclopentenylmethyl) guanine	2000
Alex White Professor Alan Calvert Professor Nicola Curtin Professor Roger Griffin Professor Herbie Newell et al.	Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase	2000
Hannah Barlow Professor Nicola Curtin Professor Alan Calvert Emeritus Professor Bernard Golding Professor Herbie Newell et al.	Resistance-modifying agents. Part 7: 2,6-Disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that inhibit nucleoside transport in the presence of α1-acid glycoprotein (AGP)	2000
Dr Johanne Bentley Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Professor Jane Endicott et al.	Structure-activity relationships and cellular effects of novel purine- and pyrimidine-based cyclin dependent kinase inhibitors	2000
Professor Alan Calvert	Temozolomide and treatment of malignant glioma	2000
Professor Roger Griffin Hannah Barlow Professor Nicola Curtin Professor Alan Calvert Emeritus Professor Bernard Golding et al.	2,6-Disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines as nucleoside transport inhibitors: Structure-activity relationships for binding to alpha(1)-acid glycoprotein (AGP)	1999
Dr Andrew Hughes Professor Alan Calvert	An update on thymidylate synthase inhibitors	1999
Professor Herbie Newell Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Dr Ashleigh Gibson et al.	Antiproliferative cyclin dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.	1999
Dr Brian Angus Dr Sathyarathna Gokul Professor Alan Calvert Professor John Lunec	Bcl-2 expression is a potential prognostic co-factor with P53- mutation status in epithelial ovarian carcinoma	1999
Professor Alan Calvert Dr Martin Highley Professor John Lunec Professor Alan Boddy	Carboplatin and paclitaxel, alone and in combination: Dose escalation, measurement of renal function, and role of the p53 tumor suppressor gene	1999
Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Dr Ashleigh Gibson Emeritus Professor Bernard Golding et al.	In vitro growth activity of novel purine- and pyrimidine-based CDK1 and CDK2 inhibitors.	1999
Peter Smith Professor Alan Calvert Professor Herbie Newell Professor Nicola Curtin	MTA (LY231514) induced intracellular dNTP pool pertubations are alleviated by salvage of pre-formed purines and pyrimidines	1999
Professor Alan Calvert	MTA, a novel multitargeted antifolate, from preclinical to phase I and beyond: summary and conclusions	1999
Peter Smith Hannah Barlow Professor Alan Calvert Professor Nicola Curtin Emeritus Professor Bernard Golding et al.	Novel dipyridamole analogues potentiate the in vitro activity of MTA (LY231514) in the presence of alpha(1)-acid glycoprotein.	1999
Dr Michael Tilby Professor Alan Calvert Professor Herbie Newell	Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: Effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels	1999
Dr Andrew Hughes Melanie Griffin Professor Alan Calvert Professor Herbie Newell Professor Alan Boddy et al.	Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days	1999
Professor Ruth Plummer Professor Alan Calvert Dr Martin Highley	Phase I trial of ZD9331 in adult patients with refractory solid malignancies administered by 30-min infusion on days 1 and 8 with the cycle repeated every 3 weeks	1999
Professor Alan Calvert	Phase II study results on safety and efficacy of CAELYX®(DOXIL®) in combination with paclitaxel in the treatment of metastatic breast cancer	1999
Michael Batey Kevin Fishwick Dr Ashraf Azzabi Professor Herbie Newell Professor Alan Calvert et al.	Population pharmacokinetics of CMF in the adjuvant treatment of breast cancer	1999
Professor Nicola Curtin Professor Alan Calvert Professor barbara Durkacz Professor Herbie Newell	Potentiation of temozolomide and topotecan cytotoxicity by PARP inhibitors in a panel of human cancer cell lines.	1999
Professor Nicola Curtin Suzanne Kyle Lan Wang Professor barbara Durkacz Professor Roger Griffin et al.	Potentiation of temozolomide and topotecan growth inhibition by novel potent benzimidazole poly(ADP-ribose) polymerase (PARP) inhibitors	1999
Professor Nicola Curtin Professor Alan Calvert Emeritus Professor Bernard Golding Professor Roger Griffin Professor Herbie Newell et al.	Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced α1-acid glycoprotein binding	1999
Dr Christopher Calabrese Huw Thomas Michael Batey Professor Nicola Curtin Professor Roger Griffin et al.	Preclinical pharmacology of novel substituted benzimidazoles - potent inhibitors of poly (ADP-ribose) polymerase	1999
Peter Smith Professor Alan Calvert Professor Herbie Newell Professor Nicola Curtin	Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines	1999
Dr John Lunn Professor Steve Wedge Professor Herbie Newell Professor Alan Calvert	O⁶-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma	1998
Professor Alan Calvert Professor Nicola Curtin Emeritus Professor Bernard Golding Professor Roger Griffin Professor Herbie Newell et al.	2-phenylbenzimidazole-4-carboxamides are potent inhibitors of the DNA repair enzyme poly(ADP-ribose)-polymerase (PARP)	1998
Professor Herbie Newell Professor Alan Calvert Professor Anne Dickinson Professor Frederick Campbell Professor Nicola Curtin et al.	Dipyridamole potentiates antipurine antifolate activity in the presence of hypoxanthine in tumor cells but not in normal tissues in vitro	1998
Professor Alan Calvert Professor Herbie Newell Professor Nicola Curtin	Dipyridamole selectively potentiates antipurine antifolates in human tumour cell lines but not normal tissue targets of dose-limiting toxicity	1998
Professor Jane Endicott Professor Martin Noble Professor Alan Calvert Professor Nicola Curtin Emeritus Professor Bernard Golding et al.	Insights into CDK inhibitor design from X-ray crystallographic studies	1998
Professor Alan Calvert Professor Nicola Curtin Professor Jane Endicott Emeritus Professor Bernard Golding Professor Roger Griffin et al.	O-6-alkylguanines as selective inhibitors of cyclin dependent kinases	1998
Dr Andrew Hughes Melanie Griffin Professor Alan Calvert Andrew Johnston Professor Herbie Newell et al.	Pharmacokinetic interactions in a phase I study of nolatrexed (AG337, THYMITAQ ^TM) and paclitaxel in patients with advanced solid tumours	1998
Peter Smith Professor Herbie Newell Professor Alan Calvert Professor Nicola Curtin	Potentiation of the in vitro activity of the multi-targeted antifolate MTA (LY231514) by dipyridamole	1998
Professor Alan Boddy Gordon Taylor Professor Herbie Newell Professor Alan Calvert	Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given prolonged administration in patients with solid tumors	1998
Professor Roger Griffin Professor Alan Calvert Professor Nicola Curtin Professor Herbie Newell Emeritus Professor Bernard Golding et al.	Resistance-modifying agents. 5.1 Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP)	1998
Professor Alan Boddy Huw Thomas Lynsey Robson Professor Alan Calvert	A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer	1997
Professor Alan Calvert	Good manners for the pharmaceutical industry	1997
Professor Alan Calvert Dr Andrew Hall Professor John Lunec Professor Herbie Newell Professor Andrew Pearson et al.	The relationship between intrinsic thymidylate synthase expression and sensitivity to THYMITAQ® in human leukaemia and colorectal carcinoma cell lines	1997
Professor Steve Wedge Fiona Chapman Gordon Taylor Huw Thomas Professor Alan Boddy et al.	A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid	1996
Professor Alan Calvert Professor Herbie Newell	A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve	1996
Professor Alan Calvert Dr John Anderson Professor David Neal Professor John Lunec	Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer	1996
Professor Herbie Newell Huw Thomas Professor Alan Calvert	Bioequivalence assessment of etoposide phosphate and etoposide using pharmacodynamic and traditional pharmacokinetic parameters	1996
Professor Alan Boddy Huw Thomas Professor Herbie Newell Professor Alan Calvert Lynsey Robson et al.	Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: A cancer research campaign phase I/II committee study	1996
Dr Christine Arris Dr Christine Bleasdale Professor Alan Calvert Professor Nicola Curtin Emeritus Professor Bernard Golding et al.	Mechanism-based inhibition of O-6-methylguanine-DNA methyltransferase.	1996
Professor Roger Griffin Alex White Kenneth Bowman Professor Alan Calvert Professor Nicola Curtin et al.	Novel benzimidazole and quinazolinone inhibitors of the DNA repair enzyme Poly(ADP-ribose)polymerase	1996
Kevin Fishwick Lynsey Robson Professor Alan Calvert	Phase I study of pharmacologically based dosing of carboplatin with filgrastim support in women with epithelial ovarian cancer	1996
Dr Andrew Hall Professor Alan Calvert Dr James Sunter Professor Herbie Newell	The relationship between tumour glutathione concentration, glutathione S-transferase isoenzyme expression and response to single agent carboplatin in epithelial ovarian cancer patients	1996
Professor Farhad Kamali Russell Wallace Professor Alan Calvert	The safety of sumatriptan administration 2 h after subcutaneous injection of alniditan, a new anti-migraine drug, in healthy volunteers	1996
Professor Alan Calvert	Cancer-research campaign phase-II trail of temozolomide in metastatic melanoma	1995
Professor Alan Calvert Professor Alan Boddy Dr Andrew Hughes Lynsey Robson Huw Thomas et al.	Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions.	1995
Gordon Taylor Professor Alan Boddy Professor Alan Calvert Andrew Johnston Professor Herbie Newell et al.	Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridplthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusion	1995
Professor Steve Wedge Gordon Taylor Professor Alan Boddy Professor Alan Calvert Professor Herbie Newell et al.	Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolic acid (lometrexol) administered with an oral folic acid supplement	1995
Professor Alan Calvert Professor John Lunec	Molecular characterisation of 2 cell-lines selected for resistance to the folate-based thymidylate synthase inhibitor, ZD1694	1995
Lynsey Robson Professor Alan Calvert	Oral folic acid improves lometrexol toxicity profile: A phase I study	1995
Professor Herbie Newell Professor Alan Calvert	Pharmacokinetics and Pharmacodynamics of Prolonged Oral Etoposide in Women with Metastatic Breast-Cancer	1995
Professor Herbie Newell Gordon Taylor Professor Alan Calvert	Phase I and pharmacokinetic study of a water-soluble etoposide prodrug, etoposide phosphate (BMY-40481)	1995
Professor Alan Calvert	Quinazoline antifolate thymidylate synthase inhibitors: replacement of glutamic acid in the C2-methyl series	1995
Professor Alan Calvert	Role of Taxanes in Cancer-Therapy	1995
Professor Roger Griffin Professor Nicola Curtin Professor Herbie Newell Emeritus Professor Bernard Golding Professor barbara Durkacz et al.	The Role of Inhibitors of Poly(Adp-Ribose) Polymerase as Resistance-Modifying Agents in Cancer-Therapy	1995
Professor Alan Calvert	The use of granulocyte-colony-stimulating factor to deliver 4 cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast-cancer	1995
Professor Alan Calvert	A Cancer-Research Campaign (Crc) Phase-Ii Trial of Cb10-277 Given by 24-Hour Infusion for Malignant-Melanoma	1994
Professor Alan Calvert	A Dose-Finding Study of Granisetron, a Novel Antiemetic, in Patients Receiving High-Dose Cisplatin	1994
Professor Alan Calvert	A strategy for the design of membrane-permeable folylpoly- gamma-glutamate synthetase inhibitors - bay-region-substituted 2-desamino-2-methyl-5,8-dideazafolate analogs	1994
Professor Alan Calvert	Carboplatin and granulocyte-colony-stimulating factor as first-line treatment for epithelial ovarian-cancer - a phase-I dose-intensity escalation study	1994
Professor Alan Calvert	Dose optimization of carboplatin in adults	1994
Dr Christine Arris Dr Christine Bleasdale Professor Alan Calvert Professor Nicola Curtin Emeritus Professor Bernard Golding et al.	Probing the active site and mechanism of action of O-6-methylguanine-DNA methyltransferase with substrate-analogs to (O-6-substituted guanines)	1994
Professor Alan Calvert	The Synthesis and Thymidylate Synthase Inhibitory Activity of L-Gamma-L-Linked Dipeptide and L-Gamma-Amide Analogs of 2- Desamino-2-Methyl-N(10)-Propargyl-5,8-Dideazafolic Acid (Ici- 198583)	1994
Professor Alan Calvert	Advanced epithelial ovarian-cancer - 1993 Consensus Statements	1993
Professor Herbie Newell Professor Andrew Pearson Dr Michael Keir Professor Alan Calvert	Carboplatin Pharmacokinetics in Children - the Development of a Pediatric Dosing Formula	1993
Professor Alan Calvert	Comparison of myelotoxicity relating to 2 chemotherapy regimens for small-cell lung-cancer (SCLC)	1993
Professor Alan Calvert	Gamma-linked dipeptide analogues of 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid as antitumour agents	1993
Professor Alan Calvert Angela Robinson Professor Herbie Newell	Long-Term Oral Etoposide in Metastatic Breast-Cancer - Clinical and Pharmacokinetic Results	1993
Professor Herbie Newell Professor Alan Calvert	Phase-I trial with pharmacokinetics of Cb10-277 given by 24 hours continuous infusion	1993
Professor Alan Calvert	Platinum Complexes in Cancer Medicine - Pharmacokinetics and Pharmacodynamics in Relation to Toxicity and Therapeutic Activity	1993
Professor Herbie Newell Professor Alan Calvert	Preclinical, Phase-I and Pharmacokinetic Studies with the Dimethyl Phenyltriazene-Cb10-277	1993
Professor Herbie Newell Professor Alan Calvert	Clinical Pharmacokinetics of the Anthrapyrazole Ci-941 - Factors Compromising the Implementation of a Pharmacokinetically Guided Dose Escalation Scheme	1992
Professor Alan Calvert Professor Herbie Newell	Future directions with carboplatin: Can Therapeutic Monitoring, High-Dose Administration, and Hematologic Support with Growth Factors Expand the Spectrum Compared with Cisplatin?	1992
Professor John Lunec Professor Alan Calvert	Human Lymphoblastoid-Cells with Acquired-Resistance to C²- Desamino-C²-Methyl-N¹⁰-Propargyl-5,8-Dideazafolic Acid - a Novel Folate-Based Thymidylate Synthase Inhibitor	1992
Professor Herbie Newell Professor Alan Calvert	Phase-I Trial of the Anthrapyrazole Ci-941 - Prospective Evaluation of a Pharmacokinetically Guided Dose-Escalation	1992
Professor Alan Calvert	Quinazoline antifolate thymidylate synthase inhibitors: difluoro-substituted benzene ring analogs	1992
Professor Alan Calvert	Structural basis for recognition of polyglutamyl folates by thymidylate synthase	1992
Professor Alan Calvert	Syntheses and Thymidylate Synthase Inhibitory Activity of the Poly-Gamma-Glutamyl Conjugates of N- 5- N-(3,4-Dihydro-2- Methyl-4-Oxoquinazolin-6-Ylmethyl)-N-Methylamino -2-Thenoyl -L- Glutamic Acid (Ici D1694) and Other Quinazoline Antifolates	1992
Professor Alan Calvert	Anthrapyrazole CI941 - a highly-active new agent in the treatment of advanced breast cancer	1991
Professor Alan Calvert	Combining cisplatin and carboplatin complementary or contradictory	1991
Geoffrey Taylor Professor Alan Calvert	ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study	1991
Professor Alan Calvert	Phase-II trial of trimelamol in refractory ovarian cancer	1991
Professor Alan Calvert	Quinazoline antifolate thymidylate synthase inhibitors: bridge modifications and conformationally restricted analogs in the C2-methyl series	1991
Professor Alan Calvert	Quinazoline antifolate thymidylate synthase inhibitors: heterocyclic benzoyl ring modifications	1991
Professor Alan Calvert	Quinazoline antifolates inhibiting thymidylate synthase - 4- thio-substituted analogs	1991
Professor Herbie Newell Geoffrey Taylor Professor Alan Calvert	The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N¹⁰-propargyl-5,8-dideazafolic acid (ICI 198583)	1991
Professor Alan Calvert	The Costs of Carboplatin Treatment	1991
Professor Herbie Newell Professor Alan Calvert	The pharmacokinetics of the quinazoline antifolate ICI D 1694 in mice and rats	1991
Professor Herbie Newell Sarah Morgan Professor Alan Calvert	The renal effects of N-¹⁰-propargyl-5,8-dideazafolic acid (CB 3717) and a non-nephrotoxic analog ICI D 1694, in mice	1991
Professor Alan Calvert	Thymidylate synthase inhibitors: the in vitro activity of a series of heterocyclic benzoyl ring modified 2-desamino-2- methyl-N¹⁰-substitted-5,8-dideazafolates	1991
Professor Alan Calvert	21-day cycles of oral etoposide in heavily pretreated metastatic germ-cell cancer	1990
Geoffrey Taylor Professor Alan Calvert	Activity of the thymidylate synthase inhibitor 2-desamino-N-¹⁰- propargyl-5,8-dideazafolic acid and related-compounds in murine (L1210) and human (W1l2) systems in Vitro and in L1210 in Vivo	1990
Professor Alan Calvert	Quinazoline antifolate thymidylate synthase inhibitors - 2'- fluoro-N-¹⁰-propargyl-5,8-dideazafolic acid and derivatives with modifications in the C-2 position	1990
Professor Alan Calvert	Quinazoline antifolate thymidylate synthase inhibitors: alkyl, substituted alkyl, and aryl substituents in the C-2 position	1990
Professor Alan Calvert	Quinazoline antifolate thymidylate synthase inhibitors: benzoyl ring modifications in the C2-methyl series	1990
Professor Alan Calvert	Recent advances in cancer-chemotherapy	1990
Professor Herbie Newell Professor Alan Calvert	Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma	1989
Professor Alan Calvert Professor Herbie Newell	Carboplatin Dosage - Prospective Evaluation of a Simple Formula Based on Renal-Function	1989
Professor Alan Calvert	Cisplatin Carboplatin Cross-Resistance in Ovarian-Cancer	1989
Professor Herbie Newell Professor Alan Calvert	Determination of the Anthrapyrazole Anticancer Drug Ci-941 in Plasma and Urine by Solid-Phase Extraction and High-Performance Liquid-Chromatography	1989
Geoffrey Taylor Professor Alan Calvert	Estimation of the in vitro and in vivo inhibitory effects of antifolates upon thymidylate synthase (TS) in whole cells	1989
Professor Alan Calvert	Introduction - a history of the progress of anticancer chemotherapy	1989
Professor Alan Calvert	Phase-I trial and pharmacokinetics of trimelamol (N²,N⁴,N⁶- trihydroxymethyl-N²,N⁴,N⁶-trimethylmelamine)	1989
Professor Herbie Newell Professor Alan Calvert	Preclinical and Clinical Pharmacokinetic Studies with 1-(4-Carboxyphenyl)-3, 3-Dimethyl Triazene (CB10-277)	1989
Professor Alan Calvert	Quinazoline antifolate thymidylate synthase inhibitors: nitrogen, oxygen, sulfur, and chlorine substituents in the C2 position	1989
Professor Alan Calvert	Quinazoline antifolates inhibiting thymidylate synthase - computer modeling of the N-¹⁰ substituent	1989
Professor Herbie Newell Professor Alan Calvert	Quinazoline antifolates inhibiting thymidylate synthase: 2- desamino derivatives with enhanced solubility and potency	1989
Professor Herbie Newell Professor Alan Calvert	The pharmacokinetics and toxicity of the anthrapyrazole anti- cancer drug Ci-941 in the mouse - a guide for rational dose escalation in patients	1989
Professor Herbie Newell Gordon Taylor Professor Alan Calvert	Thymidylate synthase - a target for anticancer drug design	1989
Professor Alan Calvert	Carboplatin or cisplatin	1988
Professor Herbie Newell Professor Alan Calvert	Development of an assay for the estimation of N¹⁰-propargyl- 5,8-dideazafolic acid polyglutamates in tumor cells	1988
Professor Herbie Newell Professor Alan Calvert	Formation and retention and biological activity of N¹⁰- propargyl-5,8-dideazafolic acid (CB 3717) polyglutamates in L1210 cells in vitro	1988
Professor Alan Calvert	Phase-II study of the antifolate N¹⁰-propargyl-5,8-dideazafolic acid (CB3717) in advanced breast-cancer	1988
Professor Alan Calvert	A Phase II study of Carboplatin in metastatic transitional cell carcinoma of the bladder	1987
Professor Alan Calvert	High dose carboplatin in the treatment of lung-cancer and mesothelioma: a phase I dose escalation study	1987
Professor Herbie Newell Professor Alan Calvert	Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin	1987
Professor Alan Calvert Professor Herbie Newell	Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB3717)	1987
Professor Herbie Newell Professor Alan Calvert	Tumor necrosis factor in man - clinical and biological observations	1987
Professor Alan Calvert Professor Herbie Newell	A Phase-I Evaluation of the Quinazoline Antifolate Thymidylate Synthase Inhibitor, N-10-Propargyl-5,8-Dideazafolic Acid, Cb3717	1986
Professor Alan Calvert	Increased Thymidylate Synthase in L1210 Cells Possessing Acquired-Resistance to N10-Propargyl-5,8-Dideazafolic Acid (CB 3717) - Development, Characterization, and Cross-Resistance Studies	1986
Professor Herbie Newell Professor Alan Calvert	Pharmacokinetics of the thymidylate synthase inhibitor N¹⁰- propargyl-5,8-dideazafolic acid (CB 3717) in the mouse	1986
Professor Alan Calvert	Phase-II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma	1986
Professor Alan Calvert	Phase-II trials in metastatic bladder-cancer	1986
Professor Alan Calvert	Quinazoline antifolates inhibiting thymidylate synthase: benzoyl ring modifications	1986
Professor Alan Calvert	Quinazoline antifolates inhibiting thymidylate synthase: variation of the amino-acid	1986
Professor Herbie Newell Professor Alan Calvert	The effect of the nucleoside transport inhibitor dipyridamole on the incorporation of H³ thymidine in the rat	1986
Professor Alan Calvert	Carboplatin - a very active new cisplatin analog in the treatment of small cell lung cancer	1985
Professor Alan Calvert Professor Herbie Newell	Phase-I Studies with Carboplatin at the Royal-Marsden-Hospital	1985
Professor Alan Calvert Professor Herbie Newell	Quinazoline antifolates inhibiting thymidylate synthase: variation of the N-¹⁰ substituent	1985
Professor Herbie Newell Professor Alan Calvert	The clinical pharmacokinetics of the novel antifolate N¹⁰- propargyl-5,8-dideazafolic acid (CB 3717)	1985
Professor Alan Calvert	Inhibition of thymidylate synthetase by the new quinazoline antifolate, CB 3717: enzyme purification and Kinetics	1984
Geoffrey Taylor Professor Alan Calvert	Modulation of anti-metabolite effects: effects of thymidine on the efficacy of the quinazoline based thymidylate synthetase inhibitor, CB3717	1984
Professor Herbie Newell Professor Alan Calvert	Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function	1984
Geoffrey Taylor Professor Alan Calvert	Plasma nucleoside and base levels following treatment with the new thymidylate synthetase inhibitor-CB-3717	1984
Professor Alan Calvert	Biochemical effects of a quinazoline inhibitor of thymidylate synthetase, N-(4-(N-((2-amino-4-hydroxy-6- quinazolinyl)methyl)prop-2-ynylamino)benzoyl)-L-glutamic acid (Cb3717), on human-lymphoblastoid cells	1983
Professor Alan Calvert	Phase-II study of JM8, a new platinum analog, in advanced ovarian-carcinoma	1983
Professor Herbie Newell Professor Alan Calvert	Studies on the pharmacokinetics of chlorambucil and prednimustine in man	1983
Professor Alan Calvert Professor Herbie Newell	Early Clinical-Studies with Cis-Diammine-1,1-Cyclobutane Dicarboxylate Platinum-Ii	1982
Professor Alan Calvert	A potent anti tumor quinazoline inhibitor of thymidylate synthetase: synthesis, biological properties and therapeutic results in mice	1981
Geoffrey Taylor Professor Alan Calvert	Methotrexate with thymidine, inosine, and allopurinol rescue - a phase-I clinical-study	1981
Professor Alan Calvert Gordon Taylor	Quinazoline antifolates with dual biochemical loci of action. Biochemical and Biological studies directed towards overcoming methotrexate resistance	1980
Professor Alan Calvert Gordon Taylor	The intracellular mechanism of action of metoprine (DDMP)	1980
Professor Alan Calvert	A randomised combination chemotherapy trial with and without adriamycin in squamous cell carcinoma of the head and neck	1978
Professor Alan Calvert	Improved results in combination chemotherapy of head and neck cancer using a kinetically based approach: a randomised study with and without adriamycin	1978
Professor Alan Calvert	Intrathoracic lymphoma associated with atrial arrhythmias and atrioventricular conduction defects	1978
Professor Alan Calvert	An enzyme inhibition assay for 2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine (DDMP)	1977
Professor Alan Calvert	Some observations on the human pharmacology of methotrexate	1977
Professor Alan Calvert	A kinetically based multiple drug treatment for cancer of the head and neck	1975
Professor Alan Calvert	Mortality in protein calorie malnutrition	1972